The long-term sequelae and early predictors of sequelae were determined in a chart review of 47 children with Guillain-Barre syndrome (GBS) of whom 30 had been treated with intravenous gammaglobulin (IVIG) at The Hospital for Sick Children, Toronto, Canada. Persisting long-term muscle weakness at least 2 years after recovery was present in 23% of cases. Weakness was mild and patients were functionally independent. Risk factors for long-term muscle weakness were a young age at onset and a rapid progression to maximal weakness in the acute illness (P=0.03). [1]

COMMENT. Age associated changes in the symptomatology of GBS in children have been reported previously (Sakakihara Y, Kamoshita S. 1991, see Progress in Poediatric Neurology II, PNB Publ, 1994;pp271-2). Children between 3 and 9 years are most susceptible, and the total duration of the illness is longer in younger children. Bulbar nerves are most frequently affected in the younger age group, and the facial nerve in older patients. The stage of myelinogenic maturation might explain the age-associated changes in symptomatology of GBS.